Your Health, We Care
The approval of capmatinib is based on the results of the pivotal phase 2, multicenter, non-randomized, open-label, multi-cohort GEOMETRY mono-1 study. In the population with METex14 skipping mutations (n=97), according to the assessment by the blinded independent review committee based on the RECIST v1.1 criteria, the confirmed overall response rates were 68% (95% CI, 48–84) in treatment-naive patients (n=28) and 41% (95% CI, 29–53) in previously treated patients (n=69). The study also showed that the median duration of response was 12.6 months (95% CI, 5.5–25.3) among treatment-naive patients (19 responders) receiving capmatinib, and 9.7 months (95% CI, 5.5–13.0) among previously treated patients (28 responders). The most common treatment-related adverse events (incidence ≥20%) include peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite.
from FDA,2023.03
Capmatinib inhibits c-Met, a type of tyrosine kinase that plays a role in embryonic development, org···【more】
Recommended：312026-09-01
Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-s···【more】
Recommended：292026-09-01
Capmatinib inhibits c-Met, a type of tyrosine kinase that plays a role in embryonic development, organ formation and wound healing, but is also involved in the initiation and progr···【more】
Article source：Lucius LaosRelease date：2026-01-09Recommended：31
Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor mutations that cause MET exon ···【more】
Article source：Lucius LaosRelease date：2026-01-09Recommended：29
Capmatinib targets the activity of MET receptors and blocks the tumor cell growth signaling pathway driven by MET receptors, enabling effective treatment for patients with non-smal···【more】
Article source：Lucius LaosRelease date：2024-08-08Recommended：267
Capmatinib is an oral form of c-Met kinase inhibitor with selective and ATP-competitive properties, which can significantly inhibit the proliferation and migration ability of c-Met···【more】
Article source：Lucius LaosRelease date：2024-08-08Recommended：258
Capmatinib prevents cancer cell growth by inhibiting the activity of MET tyrosine kinase, making it particularly suitable for lung cancer patients with MET14 exon skipping mutation···【more】
Article source：Lucius LaosRelease date：2024-08-08Recommended：257
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
